Fate Therapeutics (FATE) said new data from FT819's phase 1 study in patients with moderate to severe systemic lupus erythematosus showed no dose-limiting toxicities in the first three patients.
The drug showed rapid, deep and sustained depletion of CD19+ B cells in the periphery and a "favorable safety profile," the company said Monday in a statement.
One patient reaching six-month follow-up achieved clinical remission and remains free of immunosuppressive therapy, the company said.
Shares of the company rose 1.5% in recent after-hours activity.
Price: 2.7598, Change: +0.04, Percent Change: +1.46
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments